Canada Reaches Psychedelic Milestone with First Legal Group Psilocybin Therapy Session
Canada has hosted the country’s first legal group psilocybin therapy session in Vancouver, British Columbia.
Archives: news
Forgotten Psychedelics: What Is 2C-B?
2-CB isn’t the first substance that springs to mind when we hear the word psychedelic. This article provides a brief overview of the understudied 2-CB molecule.
Filament Health Announces FDA Authorization of Clinical Trial with First-ever Direct Psilocin Administration and First-ever Psychedelic Botanical Drug Candidates
Filament Health announced they have received FDA authorization to initiate the first clinical trial using naturally-sourced psychedelic substances. In addition, this approval is the first for the direct administration of psilocin rather than its prodrug psilocybin and will administer Filament’s three proprietary botanical drug candidates.
Why drugs should be not only decriminalised, but fully legalised
An article exploring the the failure of ‘The War on Drugs’ and the need for changing how we as a society view and treat drugs and drug users.
Is it Possible to Create an Ethical Psychedelics Company?
A piece by prominent psychedelic writer, Shayla Love, exploring the positive and negatives of patenting psychedelics.
Discussions With FDA Provide Guidance for Phase IIb Clinical Trial Design for DMT-Assisted Therapy for Major Depressive Disorder
Small Pharma today confirms, following positive discussions with the U.S. Food and Drug Administration, that preparations are now underway for the U.S. component of its Phase IIb clinical trial for its lead candidate, SPL026, a DMT-assisted therapy for the treatment of major depressive disorder.
Pasithea Therapeutics Corp’s (NASDAQ: KTTA) Subsidiary Pasithea Clinics Administers First Intravenous Ketamine Therapy
Pasithea Therapeutics Corp (NASDAQ: KTTA) has announced that its wholly-owned subsidiary, Pasithea Clinics, has given the first patients intravenous ketamine therapy. Ketamine has been demonstrated to be particularly successful in treating several mental diseases, such as post-traumatic stress disorder and treatment-resistant depression, in sub-anesthetic doses.
Greek Australian at the helm of Monash University’s push for the use of psychedelics to tackle mental health
The Neuromedicines Discovery Centre (NDC) will bring together expertise to propel new treatments for mental ill-health spanning the entire medicines development pipeline, from drug discovery and optimisation, to clinical trials, new healthcare guidelines and into the public policy arena.
Bill on magic mushrooms aims to make Pa. a national leader in psychedelic research
Pennsylvania could become a leader in studying magic mushrooms as a treatment for mental illness under a bill that was introduced last month in the House of Representatives and is scheduled for a Health Committee vote Tuesday in Harrisburg.
Psychedelics Help Heal Childhood Trauma, Study Finds
Researchers find that there were significantly lower levels of complex trauma symptoms and feelings of internalized shame in study participants that had used psychedelics therapeutically.